Journal article
Pyoderma gangrenosum.
- Maverakis E Department of Dermatology, University of California, Davis, Sacramento, CA, USA. emaverakis@ucdavis.edu.
- Marzano AV Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Le ST Department of Dermatology, University of California, Davis, Sacramento, CA, USA.
- Callen JP Department of Medicine, Division of Dermatology, University of Louisville, Louisville, KY, USA.
- Brüggen MC Department of Dermatology, Zurich University Hospital, Zurich, Switzerland.
- Guenova E Department of Dermatology, Lausanne University Hospital, Lausanne, Switzerland.
- Dissemond J Department of Dermatology, Venereology and Allergology, University Medical Center Essen, Essen, Germany.
- Shinkai K Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
- Langan SM Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
- 2020-10-09
Published in:
- Nature reviews. Disease primers. - 2020
English
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis that presents with rapidly developing, painful skin ulcers hallmarked by undermined borders and peripheral erythema. Epidemiological studies indicate that the average age of PG onset is in the mid-40s, with an incidence of a few cases per million person-years. PG is often associated with a variety of other immune-mediated diseases, most commonly inflammatory bowel disease and rheumatoid arthritis. The cause of PG is not well understood, but PG is generally considered an autoinflammatory disorder. Studies have focused on the role of T cells, especially at the wound margin; these cells may support the destructive autoinflammatory response by the innate immune system. PG is difficult to diagnose as several differential diagnoses are possible; in addition to clinical examination, laboratory tests of biopsied wound tissue are required for an accurate diagnosis, and new validated diagnostic criteria will facilitate the process. Treatment of PG typically starts with fast-acting immunosuppressive drugs (corticosteroids and/or cyclosporine) to reduce inflammation followed by the addition of more slowly acting immunosuppressive drugs with superior adverse event profiles, including biologics (in particular, anti-tumour necrosis factor (TNF) agents). Appropriate wound care is also essential. Future research should focus on PG-specific outcome measures and PG quality-of-life studies.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1038/s41572-020-0213-x
- PMID 33033263
- Persistent URL
- https://folia.unifr.ch/global/documents/127295
Statistics
Document views: 30
File downloads: